1. Home
  2. EZGO vs ARTL Comparison

EZGO vs ARTL Comparison

Compare EZGO & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EZGO Technologies Ltd.

EZGO

EZGO Technologies Ltd.

N/A

Current Price

$0.93

Market Cap

2.4M

ML Signal

N/A

ARTL

Artelo Biosciences Inc.

N/A

Current Price

$3.28

Market Cap

2.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EZGO
ARTL
Founded
2014
2011
Country
China
United States
Employees
N/A
N/A
Industry
Motor Vehicles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
2.5M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
EZGO
ARTL
Price
$0.93
$3.28
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
234.5K
★ 1.3M
Earning Date
08-14-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.01
$0.52
52 Week High
$3.30
$19.91

Technical Indicators

Market Signals
Indicator
EZGO
ARTL
Relative Strength Index (RSI) 49.18 38.80
Support Level $0.83 $0.52
Resistance Level $1.30 $6.81
Average True Range (ATR) 0.12 1.15
MACD 0.01 -0.05
Stochastic Oscillator 33.63 0.08

Price Performance

Historical Comparison
EZGO
ARTL

About EZGO EZGO Technologies Ltd.

EZGO Technologies Ltd is engaged in the sale of e-bicycles and battery and e-bicycle rentals, complemented by the sale of battery packs, battery cell trading and charging pile business. Its product categories include e-bicycle, Intelligent unmanned patrol car, e-motorcycle and e-moped and urban style e-tricycle. Its segments include the Battery cells and packs, electronic control system and intelligent robot segment. and the E-bicycle sales segment. The company generates maximum revenue from the Battery cells and packs segment.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: